TrialPloS one2015
Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial.
Yves Allenbach et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
59 papers cite it
this paperpooled ittrialcites it